50 related articles for article (PubMed ID: 19570011)
21. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
22. In vivo bioavailability, absorption, excretion, and pharmacokinetics of [14C]procyanidin B2 in male rats.
Stoupi S; Williamson G; Viton F; Barron D; King LJ; Brown JE; Clifford MN
Drug Metab Dispos; 2010 Feb; 38(2):287-91. PubMed ID: 19910517
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and hepatic disposition of bis[1-(ethoxycarbonyl)propyl]5-acetylamino-2,4,6-triiodoisophthalate in rats and isolated perfused rat livers.
Liu Y; Bacon ER; Ballinger K; Black CD; Illig K; McIntire GL; Wang PP; O'Neil N; Kinter L; Desai VC
Drug Metab Dispos; 2000 Jul; 28(7):731-6. PubMed ID: 10859144
[TBL] [Abstract][Full Text] [Related]
24. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
[TBL] [Abstract][Full Text] [Related]
25. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Boothe DM; Perkins J
J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
[TBL] [Abstract][Full Text] [Related]
26. Deuterium isotope effect on the toxicokinetics of monomethylamine in the rat.
Streeter AJ; Nims RW; Sheffels PR; Hrabie JA; Ohannesian L; Heur YH; Mico BA; Keefer LK
Drug Metab Dispos; 1990; 18(4):447-52. PubMed ID: 1976066
[TBL] [Abstract][Full Text] [Related]
27. In vivo metabolism and whole-blood clearance of n-nitrosomethylbenzylamine in the rat.
Kraft PL; Skipper PL; Tannenbaum SR
Cancer Res; 1980 Aug; 40(8 Pt 1):2740-2. PubMed ID: 7388824
[TBL] [Abstract][Full Text] [Related]
28. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats.
Ohtani M; Kotaki H; Uchino K; Sawada Y; Iga T
Drug Metab Dispos; 1994; 22(1):2-7. PubMed ID: 8149883
[TBL] [Abstract][Full Text] [Related]
30. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
31. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
[TBL] [Abstract][Full Text] [Related]
32. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
[TBL] [Abstract][Full Text] [Related]
33. The disposition of primaquine in the isolated perfused rat liver. Effect of dose size.
Ward SA; Mihaly GW; Nicholl DD; Edwards G; Breckenridge AM
Drug Metab Dispos; 1985; 13(4):425-9. PubMed ID: 2863105
[TBL] [Abstract][Full Text] [Related]
34. Absorption, disposition kinetics, and metabolic pathways of cyclohexene oxide in the male Fischer 344 rat and female B6C3F1 mouse.
Sauer JM; Bao J; Smith RL; McClure TD; Mayersohn M; Pillai U; Cunningham ML; Sipes IG
Drug Metab Dispos; 1997 Mar; 25(3):371-8. PubMed ID: 9172957
[TBL] [Abstract][Full Text] [Related]
35. NTP Toxicology and Carcinogenesis Studies of Dimethylvinyl Chloride (1-Chloro-2-Methylpropene) (CAS No. 513-37-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1986 Aug; 316():1-238. PubMed ID: 12748737
[TBL] [Abstract][Full Text] [Related]
36. Molecular Dynamics Simulation of Iminosugar Inhibitor-Glycosidase Complex: Insight into the Binding Mechanism of 1-Deoxynojirimycin and Isofagomine toward β-Glucosidase.
Zhou JM; Zhou JH; Meng Y; Chen MB
J Chem Theory Comput; 2006 Jan; 2(1):157-65. PubMed ID: 26626390
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and inhibitory activity of
Sansenya S; Winyakul C; Nanok K; Phutdhawong WS
Res Pharm Sci; 2020 Feb; 15(1):14-25. PubMed ID: 32180813
[TBL] [Abstract][Full Text] [Related]
38. The N-benzyl derivative of the glucosidase inhibitor 1-deoxynojirimycin shows a prolonged half-life and a more complete oral absorption in the rat compared with the N-methyl analog.
Faber ED; van den Broek LA; Oosterhuis EE; Stok BP; Meijer DK
Drug Deliv; 1998; 5(1):3-12. PubMed ID: 19570011
[TBL] [Abstract][Full Text] [Related]
39. Disposition of glycosidase inhibitors in the isolated perfused rat liver: hepatobiliary and subcellular concentration gradients of 1-deoxymannojirimycin and N-methyl-1-deoxynojirimycin.
Faber ED; Proost JH; Oosting R; Meijer DK
Pharm Res; 1994 Jan; 11(1):144-50. PubMed ID: 8140045
[TBL] [Abstract][Full Text] [Related]
40. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
